Proleukin® S 18 x 10 6 IE Pulver zur Herstellung einer Injektionslösung oder Infusionslösung
Sponsors
Cellectis, CuraCell Holding AB
Conditions
Patients with locally advanced or metastatic prostate cancer (PCa) or metastatic colorectal cancer. Participants should have progressive disease.Relapsed or refractory B-cell Non-Hodgkin lymphoma
Phase 1
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
RecruitingCTIS2022-501607-27-00
Start: 2026-01-06Target: 48Updated: 2026-01-08
A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autologous tumor-infiltrating lymphocyte-based immunotherapy in patients with metastatic colorectal or prostate cancer
RecruitingCTIS2025-521227-70-00
Start: 2025-11-13Target: 12Updated: 2025-10-01